A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

Condition:   Anaplastic Large Cell Lymphoma, ALK-Positive Intervention:   Drug: Lorlatinib Sponsors:   University of Milano Bicocca;   Pfizer Recruiting

Source: ClinicalTrials.gov - April 23, 2018 Category: Research Source Type: clinical trials